About ORPHELIA Pharma
ORPHELIA Pharma is a company based in Paris (France) founded in 2007 by Hugues Bienayme was acquired by Orphalan in November 2025.. ORPHELIA Pharma has raised $4.49 million across 2 funding rounds from investors including Bpifrance, Orphalan and Octalfa. ORPHELIA Pharma offers products and services including KIZFIZO. ORPHELIA Pharma operates in a competitive market with competitors including Ironwood Pharma, Marinus Pharma, Arvelle Therapeutics, VeraDermics and Lipum, among others.
- Headquarter Paris, France
- Founders Hugues Bienayme
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Orphelia Pharma Sas
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ORPHELIA Pharma
ORPHELIA Pharma offers a comprehensive portfolio of products and services, including KIZFIZO. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Pediatric formulation of temozolomide for treating Wilms tumor and other cancers
Funding Insights of ORPHELIA Pharma
ORPHELIA Pharma has successfully raised a total of $4.49M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $4.49 million completed in December 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $4.5M
-
First Round
First Round
(22 Oct 2018)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2019 | Amount | Series A - ORPHELIA Pharma | Valuation | Initiative OCTALFA | |
| Oct, 2018 | Amount | Debt – Conventional - ORPHELIA Pharma | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ORPHELIA Pharma
ORPHELIA Pharma has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Bpifrance, Orphalan and Octalfa. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Octalfa is engaged in creating and supporting innovative companies.
|
Founded Year | Domain | Location | |
|
CEMAG Care is focused on women's health and reproductive solutions.
|
Founded Year | Domain | Location | |
|
Corporate consultancy, advisory, and funding services are provided to businesses.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ORPHELIA Pharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - ORPHELIA Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Orphelia Pharma Comparisons
Competitors of ORPHELIA Pharma
ORPHELIA Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ironwood Pharma, Marinus Pharma, Arvelle Therapeutics, VeraDermics and Lipum, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics to treat seizure disorders
|
|
| domain | founded_year | HQ Location |
Small molecule therapies are developed for partial-onset seizures treatment.
|
|
| domain | founded_year | HQ Location |
Drug-delivery platforms for pediatric wart treatments are developed.
|
|
| domain | founded_year | HQ Location |
Developer of antibody to treat juvenile idiopathic arthritis
|
|
| domain | founded_year | HQ Location |
Medicines for chronic diseases in children are developed and provided.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Orphelia Pharma
Frequently Asked Questions about ORPHELIA Pharma
When was ORPHELIA Pharma founded?
ORPHELIA Pharma was founded in 2007 and raised its 1st funding round 11 years after it was founded.
Where is ORPHELIA Pharma located?
ORPHELIA Pharma is headquartered in Paris, France.
Who is the current CEO of ORPHELIA Pharma?
Hugues Bienayme is the current CEO of ORPHELIA Pharma. They have also founded this company.
Is ORPHELIA Pharma a funded company?
ORPHELIA Pharma is a funded company, having raised a total of $4.49M across 2 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $1.15M, raised on Oct 22, 2018.
What does ORPHELIA Pharma do?
Orphelia Pharma was founded in 2007 and is based in Paris, France, where focus is placed on developing treatments for pediatric neurology, oncology, and hematological malignancies. The lead candidate, ORP 010, is under review by the EMA for a rare hematological condition. Additional programs include ORP 005 in clinical development and ORP 009 in preclinical stages. An antiepileptic drug, vigabatrin, has been formulated for childhood epilepsy.
Who are the top competitors of ORPHELIA Pharma?
ORPHELIA Pharma's top competitors include Ironwood Pharma, Marinus Pharma and Castle Creek Biosciences.
What products or services does ORPHELIA Pharma offer?
ORPHELIA Pharma offers KIZFIZO.
Who are ORPHELIA Pharma's investors?
ORPHELIA Pharma has 4 investors. Key investors include Bpifrance, Orphalan, Octalfa, and CEMAG Care.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.